PD-1-inhibitor pembrolizumab for treatment of progressive multifocal leukoencephalopathy.

ABSTRACT: The reactivation of human JC polyoma virus (JCPyV) results in lytic infection of oligodendrocytes and neuronal cells. The corresponding clinical picture is called progressive multifocal leukoencephalopathy (PML) and results mostly from a disease-related or drug-induced immunosuppression. The opportunistic brain infection leads to a progressive demyelination of multiple areas of the central nervous system. Patients can present with various neurological deficits ranging from slight motoric symptoms to marked aphasia or reduced vigilance. Currently, there is no effective causal therapy for PML. Survival depends on the ability to achieve timely immune reconstitution. If the immune system cannot be restored, PML progresses rapidly and often ends fatally within months. Recently, some evidence fo

SUBMITTER: Mohn N 

PROVIDER: S-EPMC8129640 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature